CSIR and Laxai Sciences partners for COVID clinical trials


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ csir-laxai-sciences-hyderabad-collaborates-covid-trials
CSIR and Laxai Sciences to seek regulatory approval for clinical trials on COVID-19 patients using combinations of antiviral and host-directed therapies

Council of Scientific & Industrial Research (CSIR), in collaboration with Laxai Life Sciences Pvt. Ltd. Hyderabad has sought regulatory approval to undertake a four-arm randomized controlled phase III clinical trial. The design principle of the study is to rationally combine and repurpose antivirals (viral-entry and replication inhibitors) and host-directed therapies (HDTs) addressing the disease-spread and pathology simultaneously and to determine safety and efficacy of the three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.

The clinical trial named MUCOVIN, to be carried out in the partnership with Medanta Medicity, will include a total of 300 patients in four different groups of 75 patients in the trials to be carried for 17 to 21 days including screening and treatment.

Dr. Shekhar C. Mande, DG, CSIR highlighted that this unique combinatorial strategy (antivirals and HDTs) with repurposed drugs having complementary, additive and synergistic roles, has been adopted to increase therapeutic options for Covid-19 treatment and help recover patients faster. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology, Hyderabad and CSIR-Indian Institute of Integrative Medicine, Jammu.

Dr. Ram S. Upadhayaya CEO, Laxai Life Sciences stated that “the study aims to target viral proteins essential for its replication as well as host factors that play a crucial role in the viral life cycle and contribute to the cytokine storm”. Mr. Vamsi Maddipatla, MD of Laxai Life Sciences adds “The co-sponsorship of this study by Laxai Life Sciences highlights the company’s commitment to bringing life-saving therapies in the service of humanity”.

These clinical trials add to the several contributions CSIR has made during the pandemic and if the trial is successful, it will provide more options for treatment of COVID-19.

Tags : #CSIR #Hyderabad #LaxaiSciences #HostDirectedTherapies #Mucovin #CovidClinicalTrials

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sleep Health in India: Recognising the Public Health Impact of Sleep DisordersNovember 06, 2026
Childhood Hearing Screening: Linking Early Detection With Timely SupportNovember 06, 2026
Low-Dose Imaging in India: Accuracy Meets SafetyNovember 06, 2026
Synthetic Health Data: Powering the Future of Medical AINovember 06, 2026
AI and Clinical Trials: How ML Is Changing Patient RecruitmentNovember 05, 2026
Photon-Counting CT: What Indian Hospitals Need to KnowNovember 05, 2026
Rare Diseases in India: Navigating Diagnosis, Support and Long-Term CareNovember 05, 2026
Oral Health and Systemic Health: The Case for Routine Dental IntegrationNovember 05, 2026
KIMS Hospitals Takes Another Major Step Forward in Cancer Care with Advanced TrueBeam TechnologyNovember 04, 2026
SRM Medical College Hospital and Research Centre Hosts National Conference on Translational Regenerative Biology and Bioengineering – TRBB 2026November 04, 2026
15-Month-Old Russian Baby Avoids Lung Transplant Following Treatment at MGM HealthcareNovember 04, 2026
Why Diabetes Care Must Go Beyond Blood Sugar ControlNovember 04, 2026
Sri Sathya Sai Heart Hospital Successfully Organises Free Heart Camp, Screening for 550 Patients in Dehradun, UttarakhandNovember 04, 2026
Expert Quote | Rising Air Pollution in Delhi | Agilus DiagnosticsNovember 04, 2026
Healthcare AI Safety Officers: India's New Leadership NeedNovember 04, 2026
Next-Generation Medical Imaging: Beyond Traditional ScansNovember 04, 2026
Menopause Care in India: Building Awareness Beyond Reproductive YearsNovember 04, 2026
Endometriosis in India: Why Diagnosis and Care Coordination MatterNovember 04, 2026
Newborn Screening in India: What Families Should Know About Early TestsNovember 03, 2026
Organ Donation in India: How the Transplant Coordination Journey WorksNovember 03, 2026